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Abstract: Raltegravir has recently been licensed for the treatment of HIV-1 infection. Currently 
its use is limited to treatment-experienced patients and subjects with resistant virus. In addition 
to its activity in the setting of resistance and treatment failure, it appears to have great potential 
for ﬁ  rst-line therapy and as a switch option for subjects with intolerance to other agents, as well. 
Overall tolerability in clinical trials was excellent, and the toxicity proﬁ  le is non-overlapping 
with other agents, with no clear neuropsychiatric, gastrointestinal, or metabolic toxicity. Its 
metabolization occurs mainly via UGT1A1 rather than by the CYP450 system, resulting in 
a relatively unproblematic drug interaction proﬁ  le. The independence of the compound from 
“boosting” of drug levels with ritonavir is an attractive feature for many patients suffering from 
ritonavir-associated side effects. However, it has to be dosed twice daily.
The unique effect of raltegravir on the establishment of viral latency makes it a logical component 
of treatment attempts aiming at reducing and controlling this viral sanctuary.
This review summarizes the clinical view on the role of this novel compound in HIV therapy.
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Until 2007, highly active antiretroviral therapy (HAART) was based on combinations 
of nucleoside (NRTI), nucleotide (NtRTI), non-nucleoside reverse transcriptase inhibi-
tors (NNRTI), and protease inhibitors (PI), as well as the fusion inhibitor enfuvirtide. 
In late 2007 and early 2008, the CCR5 chemokine receptor blocker maraviroc and the 
ﬁ  rst integrase inhibitor raltegravir were licensed in most countries, representing two 
new classes of drugs with novel modes of action.
Raltegravir as the ﬁ  rst drug in its class targets HIV-1 integrase, an enzyme in the 
viral replication cycle that is essential for inserting HIV-1 proviral DNA into the host 
cell genome. In contrast to drugs from all other classes, this mode of action affects 
viral latency directly.
Mechanism of action
The complete viral life cycle requires integration of HIV-1 proviral DNA into the host cell 
genome. It occurs in three steps (Craigie 2001; Hazuda et al 2000; Lafemina et al 1992). 
The double-stranded DNA copy generated by reverse transcription of the HIV-1 viral RNA 
genome is associated with a “preintegration complex”, containing both cellular and viral 
proteins, including integrase. In a ﬁ  rst step, two nucleotides are removed from the 3’ ends 
of the proviral DNA (see Figure 1). In a second step, the proviral DNA strands are inserted 
into the host DNA and joined with it. This process is termed “strand transfer”. Subsequently, 
gaps in DNA are repaired by cellular enzymes by removing the two unpaired nucleotides 
at the 5’ end of the proviral DNA. HIV integrase catalyses the ﬁ  rst two steps.
With the discovery of selective inhibitors of strand transfer, which share a ß-diketo 
acid moiety, orally bioavailable agents came within the reach (Hazuda et al 1999, Drug Design, Development and Therapy 2008:2 282
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2004; Espeseth et al 2000; Pais et al 2002; Embrey et al 
2005). Chemical optimisation of these compounds led to 
naphthyridine derivatives and L-900612 or MK-0518 (ralte-
gravir) as a promising candidate compound.
Pharmacological properties, 
metabolism
Oral absorption of raltegravir is rapid, and oral bioavail-
ability approaches 32%. Plasma protein binding reaches 
83%. Raltegravir has a rapid initial half-life of ∼1 hour and 
a terminal half-life of ∼7 hours (Merck and Co. 2007), not 
supporting once daily administration. Steady state phar-
macokinetics are reached within 2 days after the ﬁ  rst dose 
(Iwamoto et al 2008b).
Although a high fat meal postpones the maximum plasma 
concentration by approximately 7.5 hours and decreases it by 
34%, this effect is outweighed by an augmentation of expo-
sure over time, as assessed by an increase of the area under 
the curve (AUC) by 19%. As a consequence, no speciﬁ  c 
restrictions are recommended with regard to food.
In contrast to most other antiretroviral drugs, raltegravir 
is metabolized by glucuronidation via UGT1A1 (Kassahun 
et al 2006, 2007; Merck and Co. 2007, 2008). Excretion in 
feces (51%) and in urine (31%) accounts for most of the 
elimination. No dose adjustment is required for gender, age, 
hepatic or renal function, or body mass index.
Drug interactions
Raltegravir neither induces nor inhibits cytochrome P450 
enzymes, nor is it a substrate (Iwamoto et al 2008a). There-
fore, few interactions have to be expected with other drugs 
metabolized via the P450 enzyme system, such as protease 
inhibitors (PI), non-nucleoside reverse transcriptase inhibi-
tors (NNRTI), maraviroc or frequent concomitant medication 
(eg, anticonvulsants, lipid-lowering drugs).
Of note, coadministration of raltegravir with tipranavir/
ritonavir led to a 55% decrease in raltegravir C12 h trough 
levels (Wenning et al 2006b), while reducing maximum 
concentrations (Cmax) and the AUC0–12 h less markedly (24 
and 18%).
Indinavir and Atazanavir inhibit UGT1A1. Because Indi-
navir is used rarely due to its speciﬁ  c toxicity, atazanavir is a 
likely combination partner for raltegravir. Pharmacokinetic 
studies with atazanavir, with or without ritonavir-“boosting”, 
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Figure 1 Steps of viral integration. Adapted with permission from: New Classes of Antiretrovirals: The Potential Clinical Role of Integrase Inhibitors and Entry Inhibitors. 
Clinical Care Options; Reston, Virginia; Slideset accessed at clinicaloptions.com/hiv.
Abbreviation: PIC, prointegration complex.Drug Design, Development and Therapy 2008:2 283
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showed a 30%–70% increase in raltegravir AUC (Mistry 
et al 2007). In view of its good tolerability (see below), this 
is probably not clinically relevant, and no dose adjustment is 
required for either drug. No relevant interaction was observed 
with efavirenz, etravirine, or tenofovir, either (Iwamoto et al 
2006b; Wenning et al 2006a). Rifampicin, however, reduces 
raltegravir concentrations at 12 hours by 61%(Iwamoto et al 
2006a), which appears clinically relevant. Combinations of 
raltegravir with rifampicin or similarly potent inducers should 
therefore be avoided where possible (Kassahun et al 2006, 
2007). Importantly, there appears to be no relevant interaction 
with contraceptives (Anderson et al 2007).
Antiviral activity in vitro
Marked and broad in vitro antiviral activity was observed 
against HIV-1 variants sensitive or resistant to NRTIs, 
NNRTIs, and PIs, as well as against SIV (Miller et al 2006). 
Despite considerable (40%) heterogeneity between HIV-1 
and HIV-2 integrase genes, clinical HIV-2 isolates also show 
a high sensitivity to raltegravir (Roquebert et al 2008).
Clinical trials in HIV-infected 
patients
For a list of relevant trials and a brief summary of their 
results, see Table 1.
Phase II
In protocol 004 (Markowitz et al 2007), doses of 100, 200, 
400, and 600 mg of raltegravir twice daily were compared 
to placebo (part 1) or efavirenz 600 mg (part 2) in antiretro-
viral naïve subjects in a randomized, double-blind manner, 
stratiﬁ  ed for initial HIV plasma viremia (  or   50000 
copies/mL). Minimum CD4 cell count at screening was 
100/μL, minimum viral load 5000 copies/mL. Thirty-ﬁ  ve 
subjects entered part 1 and received a 10-day course of 
raltegravir monotherapy at the doses described above or pla-
cebo. Baseline characteristics were not signiﬁ  cantly different 
between the study arms. The mean decrease at the different 
raltegravir doses after 10 days of monotherapy was 1.66 
to 2.16 log10 copies/mL, as compared with placebo (−0.17 
log10 copies/mL), with no signiﬁ  cant difference between the 
raltegravir dosage arms.
Of these trial participants, 30 entered the second part, 
together with 198 additional subjects. They were randomized 
to receive either raltegravir at the doses mentioned above, or 
efavirenz (EFV) 600 mg, all in conjunction with tenofovir 
(TDF) and lamivudine (3TC). Baseline characteristics were 
comparable between the groups, with plasma viremia rang-
ing between 4.6 and 4.8 log10 copies/mL and CD4+ T-cells 
from 271 to 314 cells/mm³. None of the study subjects 
had primary resistance to TDF, 3TC, or EFV. Viral load 
Table 1 Clinical trial results with Raltegravir (MK-0518)
Protocol Study Design Patient population Treatment Results
004 Multicenter, 
double-blind, 
randomized, 
controlled, 
dose-escalating
antiretroviral naive
(n = 198)
RGV 100, 200, 400, or 600 mg 
bid vs efavirenz 600 mg qd 
(all + lamivudine and 
tenofovir)
week 24
pVL   50 copies/mL: 85%–95% 
(RGV arms) vs 92% (efavirenz arm), p = n.s.
CD4+ T -cells (/μL): +139–175 
(RGV arm) vs +112 (efavirenz) p = n.s.
week 48
pVL   50 copies/mL: response 
sustained at 83%–88% across all arms
005 Multicenter, 
double-blind, 
randomized, 
controlled, 
dose-escalating
treatment-experienced, 
multidrug-resistant
(n = 178)
RGV 200, 400, and 600 mg 
bid vs placebo (+ optimized 
background regimen in all)
week 24
pVL: –1.8 to –1.87 log10 (RGV arms) 
vs –0.35 log10 (placebo arm)
pVL   50 copies/mL: 65%–67% 
(RGV arms) vs 13% (placebo arm)
CD4+ T -cells (/μL): +63 to +113 
(RGV arms) vs +5 (placebo arm)
BENCHMRK-1
+
BENCHMRK-2
Phase III, parallel, 
multinational, 
randomized, 
double-blind, 
placebo-controlled 
studies
treatment-experienced, 
multidrug-resistant
(n = 350; n = 349)
RGV 400 mg bid vs placebo 
(+ optimized background 
regimen in all)
week 16 (primary end-point)
pVL   400 copies/mL: 77% and 77% 
(RGV arm) vs 41% and 43% in placebo arm
pVL   50 copies per mL: 61% and 62% 
(RGV arm) vs 33 and 36% in placebo arm
CD4+ T -cells (/μL): +83 and +86 
(RGV arm) vs +31 and +40 in placebo arm
Abbreviations: RGV, raltegravir; pVL, plasma viral load.Drug Design, Development and Therapy 2008:2 284
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reduction to less than 50 copies of HIV RNA per mL was 
more rapid and signiﬁ  cantly more frequent at weeks 4 and 8 
in all raltegravir arms, but response was not different at any 
time-point thereafter up to and including week 48. CD4+ 
T-cells increased to a comparable extent in all arms. Adverse 
events were infrequent, of mild to moderate intensity, with 
no obvious difference between the treatment arms. Continued 
follow-up until week 96 conﬁ  rmed the sustained efﬁ  cacy of 
raltegravir in this study (Markowitz et al 2008).
Protocol 005 (Grinsztejn et al 2007) was a multicenter, 
randomized, double-blind, placebo-controlled dose-ranging 
trial in treatment-experienced patients. 178 patients with 
greater than 5000 HIV RNA copies per mL, a minimum of 
50 CD4+ T-cells on 3 months of stable antiretroviral therapy, 
and resistance to at least 3 drug classes were included and 
analyzed. Investigators selected an optimal background 
regimen according to all available resistance test results. 
Randomization was performed in a 1:1:1:1 fashion to ralte-
gravir doses of 200, 400, and 600 mg twice daily, or placebo, 
stratiﬁ  ed by PI resistance at baseline and prior enfuvirtide use. 
Primary end-points were week 24 response and toxicity.
Virological response was signiﬁ  cantly better for all 
raltegravir arms as compared to placebo, with no signiﬁ  cant 
difference between the raltegravir arms. This difference 
in favour of raltegravir was observed with any extent of 
resistance to the compounds of the background regimen, as 
assessed by genotypic or phenotypic sensitivity scores (GSS 
or PSS), ie, the number of drugs a patient received, which 
were predicted to be active at baseline. Use of additional 
enfuvirtide was also associated with a better virological 
outcome. There was no obvious difference of toxicity proﬁ  le 
for any raltegravir dose in comparison to placebo.
Phase III
Based on the results of the aforementioned trials, 400 mg 
twice daily was selected as a dose for the phase III studies.
MK-0518-018 and MK-0518-019 (BENCHMRK-1 and 
BENCHMRK-2 (Cooper et al 2007; Steigbigel et al 2007) 
were two parallel, double-blind, placebo-controlled studies. 
In both trials, an investigator-selected, resistance analysis-
based optimal regimen was combined with either raltegravir 
or placebo. Randomization was performed in a 2:1 manner. 
Patients were required to have triple-class resistant virus at 
baseline and HIV plasma viremia greater than 1000 copies 
per mL. BENCHMRK-1 was conducted in Europe, Asia, 
the Paciﬁ  c, and Peru, BENCHMRK-2 in the Americas. The 
primary end-point was viral suppression to   400 copies per 
mL at week 16, with virus suppression to   50 copies per mL 
and change from baseline viral load and CD4+ T-cell count 
evaluated as secondary end-points.
Baseline demographic variables and patient character-
istics were comparable between the study arms and the 
studies.
The raltegravir arms in both trials were superior over 
placebo with regard to all end-points. The difference was 
maintained irrespective of the extent of baseline resistance 
(as assessed by GSS and PSS), baseline HIV RNA levels, 
and baseline CD4+ T-cell count. There was no signiﬁ  cant 
difference with respect to toxicity between the study arms.
A superior response was sustained until week 24 in a 
combined analysis of both trials. The difference in favour of 
raltegravir persisted regardless of the background regimen. 
A repeat analysis after 48 weeks of follow-up conﬁ  rmed the 
week 24 results: The response rate (HIV RNA   50 copies per 
mL) in the raltegravir group at week 48 was 89% in combina-
tion with enfuvirtide and darunavir, when both were used for 
the ﬁ  rst time (Cooper et al 2008). This approaches response 
rates in previously untreated patients and therefore represents 
a marked improvement for subjects with resistant virus.
Toxicity
Study 005 and the BENCHMRK studies are more difﬁ  cult 
to interpret with respect to toxicity, since all participants 
received complex regimens with a high potential of untoward 
reactions, eg, gastrointestinal side effects associated with 
ritonavir-boosted protease inhibitors. However, side effects 
and laboratory abnormalities were balanced between the 
groups in both trials, with no signiﬁ  cant difference between 
the study arms. In this regard, MK-0518-004 provides a 
clearer picture, because there was a 10-day run-in mono-
therapy phase. Moreover, subsequently all subjects received 
a background regimen comprising of only tenofovir and 
lamivudine. From the 004 and 005 studies (Grinsztejn et al 
2007; Markowitz et al 2007), diarrhea, nausea, fatigue, 
and muscle aches were reported. Laboratory abnormalities 
include increases in pancreatic amylase and hepatic trans-
aminase levels. Of note, no lipid abnormalities were reported 
from the 004 study (Markowitz et al 2007).
When analyzing the phase II and III trials together, only 
a few patients on raltegravir or placebo discontinued for 
adverse events. Adverse events were mostly mild to moderate. 
Headache, nausea, and diarrhea were the most common 
treatment related adverse events occurring in  10% of 
subjects. They were evenly distributed between the arms.
Fatigue (7.9% vs 4.6%), herpes zoster (4.1% vs 0.7%), 
nasopharyngitis (6.1% vs 3.9%), and mild to moderate rash Drug Design, Development and Therapy 2008:2 285
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(5.3% vs 2.5%) not requiring treatment discontinuation, 
as well as elevated creatine phosphokinase (CPK, 3.7% 
vs 1.1%) were observed more frequently on raltegravir 
(  2% difference). Myopathy and rhabdomyolysis were also 
reported, but the causal role of raltegravir in these instances 
is unclear. It is therefore recommended that raltegravir be 
used with caution in combination with other drugs associated 
with muscle toxicity.
Overall, more hepatic laboratory events were observed 
on raltegravir. However, no clear difference was noted with 
respect to other hepatic adverse events in the total study 
population or within the subgroup of hepatitis B or C coin-
fected subjects.
In the pooled analysis, a higher rate of malignancies 
was observed in patients on raltegravir (2.5% vs 1.5% 
for placebo). After adjustment for duration of exposure, 
however, the adjusted risk of malignancy per 100 patient-
years was not signiﬁ  cantly different with a rate of 2.32 for 
raltegravir and 1.92 for the comparator groups (relative 
risk 1.209, 95% conﬁ  dence interval 0.44–4.14). Moreover, 
the malignancies occurred in subjects with prior AIDS and 
were very heterogeneous, with 8/19 in the raltegravir groups 
representing recurrent disease and the others occurring 
within three months of enrolment. This indicates no causal 
relationship to raltegravir (Merck and Co 2007).
A recent report of four cases suggests that raltegravir 
might lead to exacerbation of depression in subjects on 
psychotropic medication for mental disorders (Harris et al 
2008a), possibly due to drug-drug interactions. This observa-
tion, however, remains to be substantiated.
Raltegravir is currently classiﬁ  ed as FDA pregnancy 
category C, mainly due to lack of data on reproductive 
toxicity.
Resistance
Knowledge about resistance selection patterns for raltegravir 
is rapidly expanding, and they are yet understood incom-
pletely. Several characteristic mutations leading to typical 
amino acid exchanges were characterized in cell culture stud-
ies and conﬁ  rmed in clinical samples from trial participants 
with virological failure on raltegravir (Merck and Co 2007). 
The Q148K mutation was typically followed by an amino 
acid substitution at other positions (E138A, G140A, and 
V54I), with additional mutations developing at higher drug 
concentrations. Insertional mutagenesis conﬁ  rmed the role 
of these amino acid changes. The Q148K, E138A/Q148K, 
and E138A/G140A/Q148K resulted in a substantial fold-
shift (46- to 508-fold) in raltegravir IC50. Another study 
identiﬁ  ed the E92Q, G140S Q148H, N155H, and E157Q as 
key mutations (Malet et al 2008). Furthermore, virus car-
rying the Q148K as well as the E138A, G140A, and V54I 
changes was highly cross-resistant to elvitegravir and had 
a signiﬁ  cantly reduced sensitivity against other integrase 
inhibitors in development (Goethals et al 2008). In another 
study, mutated integrase enzymes displayed an impairment 
of enzyme function (Malet et al 2008), indicating reduced 
replicative ﬁ  tness. The clinical relevance of this observation, 
however, remains to be demonstrated. In vitro and in vivo 
data correspond very well, as the majority of patients in the 
BENCHMRK trials with virological failure on raltegravir, 
in whom genotyping was performed, exhibited mutations in 
integrase known to be associated with raltegravir resistance 
(Cooper et al 2008). This reﬂ  ects the strong selective pressure 
of the drug and its barrier to resistance, which appears lower 
than for ritonavir-boosted protease inhibitors, but somewhat 
higher than for ﬁ  rst-generation NNRTIs.
Subjects failing on raltegravir in clinical trials exhibited 
two pathways to resistance. The virus appears to reach a mod-
erate level of resistance (10- to 25-fold) by acquiring a change 
at position Q148 (H,K, or R) or the N155H. Other mutations, 
which by themselves have only limited impact on resistance 
(L74M, E92Q,T97A, E138K, G140S, V151I, G163G/R, and 
D232D/N), appear to decrease susceptibility further in con-
junction with either of the two (Hazuda et al 2007).
The observation of at least partial in vitro cross-resis-
tance between raltegravir and elvitegravir, another integrase 
inhibitor in phase III studies, was substantiated by clinical 
case studies. Two participants of an elvitegravir phase II 
trial switched to raltegravir upon failure to the study drug. 
No virological response was noted within one week. One 
subject harboured virus carrying the Q148R key raltegravir 
mutation in conjunction with others; the integrase sequence 
of the other one was not ampliﬁ  able (DeJesus et al 2007).
With respect to activity against different HIV clades, a 
recent study found no impact of clade-speciﬁ  c integrase poly-
morphisms on raltegravir sensitivity (van Baelen et al 2008).
Therapeutic potential
Raltegravir as the ﬁ  rst of its class has demonstrated high 
antiviral activity in a series of clinical trials, which have 
led to its approval for treatment-experienced subjects. Its 
optimal use in this setting is becoming increasingly clear: 
a subgroup analysis of the pooled BENCHMRK study data 
shows that response rates at week 48 were highest when 
the regimen comprised two other components for which 
sensitivity was predicted (Cooper et al 2008). Of note, Drug Design, Development and Therapy 2008:2 286
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response rates were not higher when more than two active 
components were combined with raltegravir. Therefore, 
three active components (which include raltegravir) 
achieve high response rates in treatment-experienced 
patients, which in fact are similar to those in previously 
untreated subjects.
Raltegravir also represents an important option for patients 
who do not tolerate an active agent in their combination, 
while exhibiting optimal response. In a series of 35 subjects 
responding to a regimen comprising enfuvirtide, enfuvirtide 
was replaced by raltegravir, while the rest of the regimen 
was left unchanged. Virological suppression was sustained 
until a median of 7 months of follow-up (Harris et al 2008b). 
The strategy of replacing active components by raltegravir 
is currently being investigated in several trials.
A large phase III trial currently addresses the activity of 
raltegravir in ﬁ  rst-line therapy. It is compared with the cur-
rent standard-of-care efavirenz, both in combination with 
tenofovir plus emtricitabine (trial 021). Results are expected 
for the end of 2008.
It is unclear if the more rapid increase in response rates 
in the raltegravir arms in study 004 (Murray et al 2007) in 
comparison with the efavirenz arm indicates higher antivi-
ral potency. Mathematical modelling actually suggests that 
calculations of viral clearance rates during early therapy 
depend on the mode of action of the drugs employed, ie 
on the stage of the viral life-cycle at which they interfere, 
and that this appears to make a difference only early in 
treatment (Sedaghat et al 2008). This actually challenges 
previous pathophysiological interpretations of studies on 
viral clearance rates. Should recently infected cells with 
unintegrated proviral DNA, which proceed to integration and 
virus production in the early phase of HAART, contribute 
a lot to plasma viral RNA in this phase, raltegravir might 
help a lower number of infected cells to be reached before 
later phases of viral decay are entered. That might not make 
a difference for viral RNA suppression in these later phases, 
but may reduce the viral depository of quasi-species and the 
basis for re-activation of virus from the latent pool. This 
view, however, is speculative and remains hypothetical at 
present.
Another very positive feature of the drug is its independence 
from pharmacological “boosting” with ritonavir. This makes 
it a very attractive option for patients with gastrointestinal 
side effects on ritonavir-boosted PIs and/or intolerance 
to efavirenz or nevirapine, as well as for patients in 
whom lipid abnormalities cannot be treated effectively 
during PI therapy. Several switch studies investigating 
improvement of neuropsychiatric toxicity of efavirenz or 
lipid and gastrointestinal toxicity on a ritonavir-boosted PI 
are ongoing.
Of the few relevant pharmacokinetic interactions, the 
inhibition of the metabolising enzyme UGT1A1 by atazanavir 
might even be exploited therapeutically. The concept of 
“boosting” raltegravir levels in order to circumvent twice 
daily dosing as one of the few disadvantageous features of 
the drug will be investigated in a clinical trial.
The recent approval of raltegravir and other com-
pounds active against triple-class resistant virus has been 
a breakthrough for patients with uncontrolled replication 
due to resistance. The term “paradigm shift” is frequently 
employed for this change in therapeutic perspectives. The 
rapid appearance of resistance with the associated muta-
tional changes in case of failure on raltegravir, however, 
demonstrates that suboptimal use of this novel compound 
(ie, in the context of too few active drugs) could ultimately 
lead to a similar rescue therapy situation. The BENCHMRK 
studies suggest that two other active drugs provide the 
necessary background for achieving the optimal effect of 
raltegravir.
For HIV-2, the number of treatment options unfortunately 
is far more limited than for HIV-1. In contrast to NNRTIs and 
some PIs, raltegravir appears to have comparable activity 
against HIV-2. Controlled clinical data, however, are still 
lacking. The same applies to pediatric application.
Ongoing or planned clinical trials
Clinical trials are underway to investigate a switch from 
enfuvirtide or a ritonavir-boosted protease inhibitor, a 
replacement of nucleoside analogues in a PI-based combination, 
alternative ﬁ  rst-line combinations of lopinavir/ritonavir and 
raltegravir or raltegravir and tenofovir/emtricitabine, as well 
as abacavir/lamivudine and raltegravir.
The unique effect of raltegravir on viral integration 
prompted clinical studies of its impact on viral latency by 
adding raltegravir to a fully suppressive combination or 
combining it with the histone deacetylase inhibitor valproic 
acid. Furthermore, it is being investigated in combination 
with tenofovir/emtricitabine for non-occupational post-
exposure prophylaxis. Other studies address children, African 
patients and acutely infected subjects, as well as a multitude 
of pharmacokinetic questions.
Raltegravir provides an important improvement of the 
therapeutic armamentarium against HIV-1 and probably 
HIV-2. Future studies will show if its high antiviral 
activity and its effect on the establishment of viral latency Drug Design, Development and Therapy 2008:2 287
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represent the desired step forward towards life-long control 
of HIV.
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